The Timing of Acute and Late Complications Following Mastectomy and Implant-based Reconstruction.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
01 Jul 2023
Historique:
medline: 12 6 2023
pubmed: 16 7 2022
entrez: 15 7 2022
Statut: ppublish

Résumé

Implant-based breast reconstruction is a common plastic surgery procedure with well-documented clinical outcomes. Despite this, the natural history and timing of key complication endpoints are not well described. The goal of this study is to determine when patients are most likely to experience specific adverse events after implant-based reconstruction. Retrospective consecutive series of patients who received mastectomy and implant-based reconstruction over a 6-year period were included. Complications and unfavorable outcomes including hematoma, seroma, wound infection, skin flap necrosis, capsular contracture, implant rippling, and implant loss were identified. A time-to-event analysis was performed and Cox regression models identified patient and treatment characteristics associated with each outcome. Of 1473 patients and 2434 total reconstructed breasts, 785 complications/unfavorable outcomes were identified. The 12-month cumulative incidence of hematoma was 1.4%, seroma: 4.3%, infection: 3.2%, skin flap necrosis: 3.9%, capsular contracture: 5.7%, implant rippling: 7.1%, and implant loss: 3.9%. In the analysis, 332/785 (42.3%) complications occurred within 60 days of surgery; 94% of hematomas, 85% of skin necrosis events, and 75% of seromas occurred during this period. Half of all infections and implant losses also occurred within 60 days. Of the remaining complications, 94% of capsular contractures and 93% of implant rippling occurred >60 days from surgery. Complications following mastectomy and implant-based reconstruction exhibit a discrete temporal distribution. These data represent the first comprehensive study of the timing of adverse events following implant-based reconstruction. These findings are immediately useful to guide postoperative care, follow-up, and clinical trial design.

Sections du résumé

BACKGROUND/OBJECTIVE OBJECTIVE
Implant-based breast reconstruction is a common plastic surgery procedure with well-documented clinical outcomes. Despite this, the natural history and timing of key complication endpoints are not well described. The goal of this study is to determine when patients are most likely to experience specific adverse events after implant-based reconstruction.
METHODS METHODS
Retrospective consecutive series of patients who received mastectomy and implant-based reconstruction over a 6-year period were included. Complications and unfavorable outcomes including hematoma, seroma, wound infection, skin flap necrosis, capsular contracture, implant rippling, and implant loss were identified. A time-to-event analysis was performed and Cox regression models identified patient and treatment characteristics associated with each outcome.
RESULTS RESULTS
Of 1473 patients and 2434 total reconstructed breasts, 785 complications/unfavorable outcomes were identified. The 12-month cumulative incidence of hematoma was 1.4%, seroma: 4.3%, infection: 3.2%, skin flap necrosis: 3.9%, capsular contracture: 5.7%, implant rippling: 7.1%, and implant loss: 3.9%. In the analysis, 332/785 (42.3%) complications occurred within 60 days of surgery; 94% of hematomas, 85% of skin necrosis events, and 75% of seromas occurred during this period. Half of all infections and implant losses also occurred within 60 days. Of the remaining complications, 94% of capsular contractures and 93% of implant rippling occurred >60 days from surgery.
CONCLUSIONS CONCLUSIONS
Complications following mastectomy and implant-based reconstruction exhibit a discrete temporal distribution. These data represent the first comprehensive study of the timing of adverse events following implant-based reconstruction. These findings are immediately useful to guide postoperative care, follow-up, and clinical trial design.

Identifiants

pubmed: 35837894
doi: 10.1097/SLA.0000000000005574
pii: 00000658-202307000-00050
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e203-e208

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Références

Society AC. Cancer Treatment & Survivorship, Facts & Figures 2014-2015. Atlanta: American Cancer Society; 2015.
Centers for Disease Control and Prevention. February 22, 2022. Available at: http://www.cdc.gov/cancer/breast/statistics . Accessed February 22, 2022.
Jagsi R, Jiang J, Momoh AO, et al. Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol. 2014;32:919–926.
Albornoz CR, Bach PB, Mehrara BJ, et al. A paradigm shift in US breast reconstruction: increasing implant rates. Plast Reconstr Surg. 2013;131:15–23.
Nahabedian MY. Innovations and advancements with prosthetic breast reconstruction. Breast J. 2018;24:586–591.
Colwell AS, Taylor EM. Recent advances in implant-based breast reconstruction. Plast Reconstr Surg. 2020;145:421e–432e.
Sigalove S, Maxwell GP, Sigalove NM, et al. Prepectoral implant-based breast reconstruction and postmastectomy radiotherapy: short-term outcomes. Plast Reconstr Surg Glob Open. 2017;5:e1631.
Sigalove S, Maxwell GP, Sigalove NM, et al. Prepectoral implant-based breast reconstruction: rationale, indications, and preliminary results. Plast Reconstr Surg. 2017;139:287–294.
Reish RG, Lin A, Phillips NA, et al. Breast reconstruction outcomes after nipple-sparing mastectomy and radiation therapy. Plast Reconstr Surg. 2015;135:959–966.
Alderman AK, Wilkins EG, Kim HM, et al. Complications in postmastectomy breast reconstruction: two-year results of the Michigan Breast Reconstruction Outcome Study. Plast Reconstr Surg. 2002;109:2265–2274.
Cohen JB, Carroll C, Tenenbaum MM, et al. Breast implant-associated infections: the role of the national surgical quality improvement program and the local microbiome. Plast Reconstr Surg. 2015;136:921–929.
Cohen O, Lam G, Choi M, et al. Does the timing of chemotherapy affect post-mastectomy breast reconstruction complications? Clin Breast Cancer. 2017;17:307–315.
O’Connell RL, Rattay T, Dave RV, et al. The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study. Br J Cancer. 2019;120:883–895.
Ooi ASh, Song DH. Reducing infection risk in implant-based breast-reconstruction surgery: challenges and solutions. Breast Cancer (Dove Med Press). 2016;8:161–172.
Warren Peled A, Itakura K, Foster RD, et al. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg. 2010;145:880–885.
Gfrerer L, Mattos D, Mastroianni M, et al. Assessment of patient factors, surgeons, and surgeon teams in immediate implant-based breast reconstruction outcomes. Plast Reconstr Surg. 2015;135:245e–252e.
Sobti N, Weitzman RE, Nealon KP, et al. Evaluation of capsular contracture following immediate prepectoral versus subpectoral direct-to-implant breast reconstruction. Sci Rep. 2020;10:1137.
Wagner RD, Braun TL, Zhu H, et al. A systematic review of complications in prepectoral breast reconstruction. J Plast Reconstr Aesthet Surg. 2019;72:1051–1059.
Momoh AO, Ahmed R, Kelley BP, et al. A systematic review of complications of implant-based breast reconstruction with prereconstruction and postreconstruction radiotherapy. Ann Surg Oncol. 2014;21:118–124.
Fischer JP, Wes AM, Tuggle CT, et al. Mastectomy with or without immediate implant reconstruction has similar 30-day perioperative outcomes. J Plast Reconstr Aesthet Surg. 2014;67:1515–1522.
Chow I, Hanwright PJ, Hansen NM, et al. Predictors of 30-day readmission after mastectomy: a multi-institutional analysis of 21,271 patients. Breast Dis. 2015;35:221–231.
Sinha I, Pusic AL, Wilkins EG, et al. Late surgical-site infection in immediate implant-based breast reconstruction. Plast Reconstr Surg. 2017;139:20–28.
Nava MB, Pennati AE, Lozza L, et al. Outcome of different timings of radiotherapy in implant-based breast reconstructions. Plast Reconstr Surg. 2011;128:353–359.
Peled AW, Foster RD, Esserman LJ, et al. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast Reconstr Surg. 2012;130:503–509.
Peled AW, Sears M, Wang F, et al. Complications after total skin-sparing mastectomy and expander-implant reconstruction: effects of radiation therapy on the stages of reconstruction. Ann Plast Surg. 2018;80:10–13.
Wang F, Peled AW, Chin R, et al. The impact of radiation therapy, lymph node dissection, and hormonal therapy on outcomes of tissue expander-implant exchange in prosthetic breast reconstruction. Plast Reconstr Surg. 2016;137:1–9.
Reish RG, Damjanovic B, Austen WG, et al. Infection following implant-based reconstruction in 1952 consecutive breast reconstructions: salvage rates and predictors of success. Plast Reconstr Surg. 2013;131:1223–1230.
Browne JP, Jeevan R, Gulliver-Clarke C, et al. The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer. Cancer. 2017;123:3460–3467.
Sinnott CJ, Pronovost MT, Persing SM, et al. The impact of premastectomy versus postmastectomy radiation therapy on outcomes in prepectoral implant-based breast reconstruction. Ann Plast Surg. 2021;87(suppl 1):S21–S27.
Hammond JB, Kosiorek HE, Cronin PA, et al. Capsular contracture in the modern era: a multidisciplinary look at the incidence and risk factors after mastectomy and implant-based breast reconstruction. Am J Surg. 2021;221:1005–1010.
Thuman JM, Worbowtiz N, Jain A, et al. Impact of radiation on implant-based breast reconstruction in prepectoral versus submuscular planes. Ann Plast Surg. 2021;86(suppl 5):S560–S566.

Auteurs

Rachel B Jimenez (RB)

Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.

Kathryn Packowski (K)

Department of Surgery, Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA.

Nora Horick (N)

Biostatistics Center, Massachusetts General Hospital, Boston, MA.

Nikki Rosado (N)

Department of Surgery, Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA.

Sachin Chinta (S)

Department of Surgery, Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA.

Daniel J Koh (DJ)

Department of Surgery, Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA.

Nikhil Sobti (N)

Department of Surgery, Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA.

Michelle C Specht (MC)

Department of Surgery, Division of Breast Surgery, Massachusetts General Hospital, Boston, MA.

Eric C Liao (EC)

Department of Surgery, Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH